PARIS (dpa-AFX) - Galapagos NV (GLPG) has dosed the first patient in a phase
IIa study evaluating GLPG2222 as an add-on to *Kalydeco in adult subjects with a
diagnosis of cystic fibrosis harboring one F508del CFTR mutation and one...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.